Biotechnology company Illumina, Inc. (NASDAQ: ILMN) on Wednesday announced financial results for the second quarter of 2023.
- Second-quarter revenue came in at $1.18 billion, up 1% from Q2 2022; a 3% increase on a constant currency basis
- Net loss per share was $1.48 in Q2, compared to a loss per share of $3.40 in the year-ago quarter
- On an adjusted basis, it was earnings of $0.32 per share for Q2 2023, compared to $0.57 per share last year
- The company expects fiscal year 2023 consolidated revenue growth of approximately 1%
- It is looking for a loss in the range of $2.08 per share to $1.93 per share for fiscal 2023
- Full-year adjusted earnings per share is expected to be in the range of $0.75 to $0.90
Most Popular
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the
Colgate-Palmolive (CL) Q1 2025 Earnings: Key financials and quarterly highlights
Colgate-Palmolive Company (NYSE: CL) reported its first quarter 2025 earnings results today. Net sales decreased 3.1% year-over-year to $4.9 billion. Organic sales growth was 1.4%. Net income attributable to Colgate-Palmolive Company rose
Meta Platforms (META) set to report Q1 earnings. Here’s what to expect
After integrating artificial intelligence into its products, Meta Platforms, Inc. (NASDAQ: META) is investing heavily in the metaverse project. Yet, the tech giant has maintained healthy cash flows and consistently
